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One hundred and sixty-four subjects with ejection fraction (EF) , 35% and NYHA Class II (24%) or III (76%) symp-
toms received a CCM pulse generator. Patients were randomly assigned to Group 1 (n ¼ 80, CCM treatment 3
months, sham treatment second 3 months) or Group 2 (n ¼ 84, sham treatment 3 months, CCM treatment
second 3 months). The co-primary endpoints were changes in peak oxygen consumption (VO2,peak) and Minnesota
Living with Heart Failure Questionnaire (MLWHFQ). Baseline EF (29.3+ 6.7% vs. 29.8+ 7.8%), VO2,peak (14.1+ 3.0
vs. 13.6+ 2.7 mL/kg/min), and MLWHFQ (38.9+ 27.4 vs. 36.5+27.1) were similar between the groups. VO2,peak
increased similarly in both groups during the first 3 months (0.40+3.0 vs. 0.37+3.3 mL/kg/min, placebo effect).
During the next 3 months, VO2,peak decreased in the group switched to sham (20.86+ 3.06 mL/kg/min) and
increased in patients switched to active treatment (0.16+2.50 mL/kg/min). MLWHFQ trended better with treat-
ment (212.06+15.33 vs. 29.70+ 16.71) during the first 3 months, increased during the second 3 months in
the group switched to sham (þ4.70+16.57), and decreased further in patients switched to active treatment
(20.70+ 15.13). A comparison of values at the end of active treatment periods vs. end of sham treatment
periods indicates statistically significantly improved VO2,peak and MLWHFQ (P ¼ 0.03 for each parameter).
Conclusion In patients with heart failure and left ventricular dysfunction, CCM signals appear safe; exercise tolerance and quality of life
(MLWHFQ) were significantly better while patients were receiving active treatment with CCM for a 3-month period.
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Medical and device-based therapies have favourably impacted on
outcomes in patients with chronic heart failure (CHF). Cardiac
resynchronization therapy (CRT) has become the standard of
care for patients with symptomatic heart failure and delayed myo-
cardial activation, indexed by a prolonged QRS duration.1 CRT
improves ventricular contractile strength, quality of life, exercise
tolerance, and reduces mortality and hospitalizations. However,
it is estimated that less than half of heart failure patients have dys-
synchrony2 and as many as 30% of implanted patients are con-
sidered non-responders.3
A new form of electrical therapy, called cardiac contractility modu-
lation (CCM), was proposed for enhancing ventricular contractile
strength independent of the synchrony of myocardial contrac-
tion.4,5 Preclinical studies indicate that CCM signals can enhance
contractile performance acutely4,6 and that normalization of myo-
cardial gene programmes, protein phosphorylation, and reverse
remodelling are implicated during long-term CCM signal delivery
in animal models of heart failure.7
CCM signals are delivered 30–40 ms after detection of local
myocardial activation during the absolute refractory period.
Thus, although 100 times the amount of energy is delivered
during a CCM pulse than during a standard pacemaker impulse,
these signals do not initiate a contraction, recruit additional con-
tractile elements, or modify the activation sequence and there is
no additional action potential (as would be observed with paired
pacing or post-extra systolic potentiation).
Initial non-randomized clinical studies with short-term appli-
cation of these CCM signals in patients with heart failure have
demonstrated acute haemodynamic effects and suggested
improved quality of life and ventricular function.5 More recently,
a small double blind feasibility study in 49 patients provided pre-
liminary evidence of safety and trends to improve exercise toler-
ance and quality of life.8 Here, we describe the results of a
prospective, randomized, double blind multicentre study of the
safety and efficacy of CCM signals.
Methods
Patients
Patients were eligible for participation if they were older than 18 years,
had symptomatic heart failure (New York Heart Association functional
class II), ischaemic or idiopathic cardiomyopathy, left ventricular
ejection fraction (EF) 35%, and peak oxygen uptake (VO2,peak)
between 10 and 20 mL O2/min/kg. Patients were required to be on
appropriate, stable medical treatments for heart failure, including
(unless shown to be intolerant) a diuretic, an angiotensin-converting
enzyme inhibitor and/or angiotensin-receptor blocker and a beta-
blocker. Patients could have a pre-existing implanted pacemaker or
ICD or, if clinically indicated, could have one implanted at the same
time as the experimental CCM device. Patients were excluded if
they were eligible for CRT, if they had atrial fibrillation, recent myocar-
dial infarction (within 3 months), clinically significant angina, were hos-
pitalized for heart failure requiring intravenous treatments within 30
days, or 8900 PVCs/24 h on a baseline Holter monitor recording.
The Ethics Committee of each centre approved the study protocol
and all patients provided written informed consent.
Study design
Patients meeting basic study entry criteria underwent baseline evalu-
ations that included the following tests: New York Heart Association
(NYHA) class, 6 min hall walk test (6MW), maximal cardiopulmonary
exercise treadmill exercise test (customized slow ramp
protocol), quality of life assessment using the Minnesota Living
with Heart Failure Questionnaire (MLWHFQ), a two-dimensional
echocardiogram, and a 48 h Holter monitor test. Patients fulfilling
entry criteria underwent implantation of an OPTIMIZER
TM
System
(IMPULSE Dynamics, Orangeburg, NY, USA) which consisted of an
implanted pulse generator and three pacing leads (a standard right
atrial lead and two active fixation leads inserted into the right ventri-
cular septum).5 Haemodynamic responses to acute CCM signal appli-
cation were measured with a micromanometer catheter (Millar
Instruments, Houston, TX, USA) placed in the LV. It was required
that the maximum rate of left ventricular pressure rise (dP/dtmax, an
index of systolic function) increases at least 5% in response to CCM.
If such changes could not be achieved, even after repositioning the
electrodes, the device was not implanted and the patient was with-
drawn from the study.
Patients who underwent successful implantation were randomly
assigned either to an active CCM treatment (Group 1: device pro-
grammed to deliver CCM signals for seven 1 h periods spaced
equally over the day) or to a sham treatment group (Group 2:
device programmed to OFF) for 12 weeks (study Phase I). During
the subsequent 12-week period (study Phase II), all subjects crossed
over to the opposite treatment. Randomization occurred 2–4 weeks
following the OPTIMIZER System implant. An unblinded site clinical
investigator opened a sealed envelope containing the randomization
assignment and a technician programmed the device accordingly. Ran-
domization codes were prepared and distributed by the data coordi-
nating centre (Analytica International GmbH, Loerrach, Germany).
Following the 24-week blinded period, subjects were offered open
label access to CCM treatment. This report will deal with the
24-week blinded study period.
The major follow-up visits occurred 12 and 24 weeks following ran-
domization, at the end of Phase I and Phase II, respectively. Cardiopul-
monary stress testing, MLWFQ, 6MW, and NYHA were repeated at
these visits. Substantial efforts were made to maintain blinding of
both patients and investigators. Specifically, devices were programmed
to OFF by a technician not involved with the clinical follow-up or
evaluation of the patients preventing detection of patient assignment
by the testing physician. Devices were reprogrammed at the end of
each visit to ON or OFF according to group assignment by the
same technician.
A core lab blinded to assignment group was used to assess peak
oxygen consumption (VO2,peak) from the cardiopulmonary stress test.
Statistics
The prospectively defined co-primary efficacy endpoints of this study
were the difference between end of phase measurements of
VO2,peak and MLWHFQ. The statistical analysis compared each end-
point between randomization groups using the classical methods
described by Fleiss9 and Armitage and Hills10 for the analysis of data
from a two-period crossover study. The analysis is based on a t-test
comparing the mean within-patient differences measured between
the end of study Phase I and the end of study Phase II. Our strategy
was to first assess whether there was evidence of a carryover effect
as we believe the use of data from both periods would only be reason-
able in the absence of such an effect. If no evidence of a carryover
effect could be found, we would test for treatment differences using
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the aforementioned t-test. The t-test is based on the contrast formed
by the end of period measures.
Sample size calculations were performed assuming that the standard
deviation of the difference in VO2,peak between periods of active and
sham therapy is 2.75 O2/kg/min. On the basis of a two-side 0.05
level t-test, a total sample size of 160 provides 80% power to detect
a within-patient difference of 0.90 ml O2/kg/min or more in VO2,peak
between periods of active and sham treatment.
Assessment of the primary null hypotheses was based on the
intent-to-treat principle. We accounted for missing data using multiple
imputation (MI) using a Markov chain Monte Carlo approach to simu-
late period differences (15 simulated data sets were created). Those
data sets were analysed by the standard method for crossover
studies (i.e. as described in Fleiss and discussed above), and the
results were combined to produce estimates and confidence intervals
as described by Rubin.11 The variables used for the imputation were
gender, QRS duration, heart failure aetiology (ischaemic or non-
ischaemic), the baseline value of the respective endpoint (VO2,peak
and MLWHFQ) and end of period values for VO2,peak for imputations
of MLWHFQ, and end of period values of MLWHFQ for imputations
of VO2,peak. The imputations were performed using PROC MI and
PROC MIANALYZE in SAS version 9.1. With regard to completeness
of data, 66 Group 1 and 69 Group 2 had VO2,peak data at the end of
both study phases; 72 Group 1 and 73 Group 2 patients had
MLWHFQ data at the end of both study phases.
Secondary efficacy endpoints included comparisons of changes in
NYHA and 6MW. Summary values in tables and figures are expressed
as mean+ SD except as otherwise noted.
A data safety and monitoring board (DSMB) reviewed serious
adverse events on three separate occasions during the course of the
study to advise the sponsor of any imbalances in events between the
groups that might be suggestive of safety concerns. No such concerns
were ever raised.
Results
The overall flow of study subjects is summarized in Figure 1.
Between May 2002 and May 2005, 181 potential study subjects
signed informed consent to undergo baseline testing. Of these,
178 passed baseline screening and underwent the OPTIMIZER
System implantation procedure. In response to acute CCM signal
application, left ventricular dP/dtmax increased by ,5% in 12
(6.7%) subjects; the device was not implanted in these subjects
and they were withdrawn from the study.
Figure 1 Summary of the study design and flow of patients. See text for details. w/d indicates subjects who are withdrawn from the study.
dP/dtmax is maximal rate of rise of left ventricular pressure measured during the implant procedure.
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For the remaining subjects, the mean (+SD) acute rise in
dP/dtmax was 10.7+0.8%. The duration of the procedure to
implant the OPTIMIZER device was 172+74 min (range
60–330 min); the average implant duration did not vary signifi-
cantly if the patient had a prior ICD or not. With regard to place-
ment of the two RV leads, the goal was to achieve a separation of
2 cm or more. On the basis of fluoroscopic assessments at the
time of implantation, the distribution of placement of the first
RV lead was: outflow track (52%), inferior septal wall (16%),
apical region of the septum (17%), or mid-septal wall (15%). For
the second RV lead, the distribution of placement was: outflow
track (13%), inferior septal wall (38%), apical region of the
septum (33%), and mid-septal wall (16%). Sensing thresholds
(13+6 mV), pacing thresholds (0.8+ 0.7 mA), and impedances
(573+118 ohms) were similar for both leads.
Two of the patients who underwent device implantation died
before randomization (one 1 week after implantation due to
ventricular fibrillation and the other 2 days after implantation
due to worsening heart failure and renal dysfunction). CCM was
never activated in these patients. Of the remaining 164 study sub-
jects, 80 were randomized to Group 1 (CCM ON for first 12
weeks) and 84 were randomized to Group 2 (CCM OFF for
first 12 weeks). Four subjects died during the randomized
portion of the study. Nine additional patients withdrew from the
study (two for continuous pocket infection, three who underwent
heart transplant, one who developed an indication for CRT, and
three for continued worsening of heart failure). The remaining sub-
jects (n ¼ 74 in Group 1, n ¼ 77 in Group 2) completed the
6-month primary follow-up period.
Baseline characteristics
Demographics and baseline characteristics of all patients who
underwent device implantation procedure are summarized in
Table 1. The groups were reasonably well balanced for all charac-
teristics, except that there was a greater proportion of patients
with ischaemic cardiomyopthay in Group 1. Baseline features of
note included average EF 29%, VO2,peak 13.9 mL/kg/min, and
QRS duration 118 ms; 62% of subjects had an ICD. Pharmacologi-
cal treatment for heart failure was comparable between the
groups. There were no distinguishing features of the 17 subjects
who were not randomized compared with the other study
subjects.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Baseline demographics (numbers are either mean+ SD or percentages)
Group I (n 5 80) Group II (n5 84) NR (n5 17)
Age (years) 58.9+9.8 59.9+10 57.4+11.4
Gender 71 (88.8%) M 68 (81%) M 15 (88.2%) M
9 (11.2%) F 16 (19%) F 2 (11.8%) F
CHF aetiology
Ischaemic 51 (63.8%) 47 (56%) 13 (76.5%)
Idiopathic 28 (35%) 32 (38%) 4 (23.5%)
Other 1 (1.2%) 5 (6%)
Resting HR (b.p.m.) 71+11.3 72.6+12.7 74.2+12.2
Systolic BP (mmHg) 114.7+17 117.1+17.9 120+19.6
QRS Duration (ms) 119.9+28.3 116.3+26.6 121.5+33.5
NYHA
II 22 (27.5%) 17 (20%) 4 (23.5%)
III 58 (72.5%) 67 (80%) 13 (76.5%)
MLWHFQ 38.9+27.4 36.5+27.1 40.8+26
6 min walk (M) 386+103 394+102 406+88
Peak VO2 (ml O2/min/kg) 14.1+3 13.6+2.7 13.2+2
EF (%) 29.3+6.6 29.8+7.8 25.3+11.7
LV EDD (mm) 69.3+9.1 68.3+7.7 69.8+10.2
Treatments
Patients with ICD 54 (67%) 48 (57%) 9 (53%)
Patients with PM 1 (1.3%) 2 (2.4%) 1 (5.9%)
Medications
Diuretics 61 (76%) 68 (81%) 16 (94.1%)
ACE-I 58 (72.5%) 61 (73%) 12 (71%)
ARB 13 (16%) 19 (23%) 1 (6%)
b-blocker 62 (77.5%) 65 (77%) 14 (82%)
Aldosterone inhibitor 33 (41%) 41 (49%) 10 (59%)
Digoxin 31 (39%) 35 (42%) 12 (71%)
NR, not randomized due to inability to increase dP/dtmax by 5% in response to acute CCM signal application during implant and other.
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In order to assess the degree of unblinding, blinded physicians and
patients were polled at the last study visit to determine if they became
aware of their group assignment. In only two patients, both in
Group 1, was it apparent that unblinding had occurred.
Primary efficacy assessments
During Phase I, VO2,peak increased similarly in both groups by
0.4 mL/kg/min, independent of whether the device was turned
on or off (Figure 2). In the second phase of the study, however,
VO2,peak remained increased in subjects who crossed over from
sham to active treatment, whereas VO2,peak decreased by
0.8 mL/min/kg in subjects who crossed from active treatment
to sham. A formal test of carryover effect was performed and
none was noted (t ¼ 0.055, P ¼ 0.96). Likewise no significant
period effect was noted (t ¼ 1.43, P ¼ 0.15). Mean (+SD)
VO2,peak improved significantly while on active therapy compared
with sham therapy by 0.52+1.39 O2/kg/min (t ¼ 2.16, P ¼
0.032, 95% confidence interval, 0.04–0.99).
MLWHFQ (Figure 3) improved in both groups during Phase I,
but the improvement tended to be better in subjects receiving
active treatment (Group 1). As with VO2,peak, MLWHFQ trends
back towards baseline when Group 1 subjects crossed from
active to sham treatment and there was continued improvement
in Group 2 subjects who crossed from sham to active treatment.
As for VO2,peak, no carryover effect (t ¼ 1.54, P ¼ 0.13) or
period effects (t ¼ 1.67, P ¼ 0.096) were noted. Mean (+SD)
values of MLWHFQ score improved significantly while on active
therapy compared with sham therapy by 2.93+8.01 (t ¼ 2.20,
P ¼ 0.030, 95% confidence interval 0.29–5.56).
Significant differences (P, 0.05) were also noted for both
VO2,peak and MLWHFQ when using both a last observation
carried forward (LOCF) approach and the MI approach to
account for missing data. The estimated treatment effect was
very similar for all analyses. Quantitative summary of data shown
in these figures is provided in Table 2.
Secondary efficacy assessments
Changes in 6-min hall walk test (Figure 4 and Table 2) paralleled
changes in VO2,peak, increasing similarly in both groups during
the first phase, increasing further in Group 2 upon crossing over
to active treatment, and decreasing in Group 1 upon crossing
over to sham treatment.
New York Heart Association classification improved significantly
but similarly in both groups in both phases of the study. For Group
1 subjects, the percent of patients in Classes I, II, III, and IV at the
final follow-up (when the device was turned off) was 8, 46, 24, and
2%, respectively. This was compared with 9, 50, 23, and 2%,
respectively, in Group 2 subjects.
Figure 2 Changes in VO2,peak in each group compared with
their respective baseline values. Results presented for the cases
with complete data; these results agree substantively with those
based on multiple imputation. Values are means+ SEE.
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Table 2 Numerical summary of results presented in Figures 2–4 (mean+ SEE)
Difference from baseline
Phase I Phase II
Group 1 Group 2 Group 1 Group 2
Peak VO2 (mL/kg/min) 0.40+0.37 0.37+0.41 20.46+0.33 0.53+0.45
MLWHFQ 212.1+1.8 29.7+2.0 27.4+2.2 210.4+2.1
6MW (m) 16.9+8.9 10.8+8.8 26.3+10.4 19.6+9.1
Figure 3 Changes in Minnesota Living with Heart Failure
Questionnaire in each group compared with their respective
baseline values. Results presented for the cases with complete
data; these results agree substantively with those based on mul-
tiple imputation. Values are means+ SEE.
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Echocardiograms were performed at baseline and at the end of
study Phases I and II. Interpretable studies were obtained in
approximately half of the patients. There were no significant
changes in EF detected in any group at any time point in this
small sampling of patients.
Safety assessments
There were six deaths during the study, two prior to randomiz-
ation (ventricular fibrillation and worsening heart failure), one in
Group 1 during the OFF period (undetermined cause), one in
Group 2 during the OFF period, and two in Group 2 during the
ON period (sudden cardiac death and renal failure).
In total, there were 48 serious adverse events in 40 patients
during CCM OFF periods, compared with 45 serious adverse
events in 41 patients during CCM ON periods. There were 46
hospitalizations in 31 patients during CCM OFF periods, compared
with 41 hospitalizations in 31 patients during CCM ON periods.
The major reasons for hospitalizations were similar in the groups
and included worsening heart failure and pneumonia.
An overview of serious cardiovascular adverse events is
provided in Table 3. The most frequently reported events were
episodes of decompensated heart failure, atrial fibrillation, bleeding
at the OPTMIZER System implant site, and pneumonia. There
were no significant differences between ON and OFF phases in
the number or types of adverse events. Adverse events specifically
related to the device and/or the procedure as reported by the
investigators included lead dislodgement, device pocket infections,
bleeding at the insertion site, and pericardial effusion. Investigators
listed several other events as being of ‘unknown’ relationship to the
device and/or procedure, including atrial fibrillation, episodes of
heart failure exacerbations, cardiogenic shock, angina, ventricular
tachycardia, and ICD sensing defect.
Because of the crossover design, hospitalizations and mortality
were analysed for the first period only. In all, there were 14 hospi-
talizations Group 1 patients (CCM ON phase) compared with 20
hospitalizations in Group 2 patients (CCM OFF phase). In addition,
there was one death in a Group 2 patient vs. no deaths in Group 1
patients. With the relatively small sample size, the difference in
overall event-free survival between groups did not reach statistical
significance (P ¼ 0.31).
Another safety endpoint in the study was an evaluation of
whether the use of the OPTIMIZER
TM
Systems was associated
with changes in the incidence and nature of arrhythmias assessed
by Holter monitoring. At baseline, the total number of PVCs/
hour was balanced between the groups with median (range)
values of 21 (0–511) and 25 (0–712) in Groups 1 and 2,
Figure 4 Changes in 6 min hall walk test in each group com-
pared with their respective baseline values. Values are
means+ SEE.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Serious cardiovascular adverse events by treatment period [number of events (number of patients)]
Pre-implant Implant to randomization Active Sham
Number of Subjects 178 166 164 164
Total* 1 20 (20) 22 (20) 26 (22)
CHF decompensation — 1 (1) 7 (6) 8 (8)
Atrial fibrillation — — 2 (2) 3 (3)
Bleeding at OPTIMIZER Site — 4 (4) — —
Pneumonia — 2 (2) — 3 (3)
VF — — 1 (1) 1 (1)
VT 1 (1) 2 (2) 3 (2) —
Angina — — 1 (1) 3 (2)
Optimizer II pocket infection — 1 (1) 1 (1) 3 (2)
ICD sensing defect** — 4 (4) 1 (1) —
Renal failure — — 1 (1) 3 (1)
Pulmonary oedema — — 1 (1) 1 (1)
Pericardial effusion — 1 (1) 1 (1) —
Cardiogenic shock — — 1 (1) —
Optimizer II lead dislodgement — 2 (2) 1 (1) —
There were no statistically significant differences in the rate of events between active and sham periods (McNemar’s statistic based on the exact binomial probability).
*Includes all serious events reported by investigators.
**All due to either T-wave over-sensing or the need for ICD lead repositioning.
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respectively. During ON periods, there was a median of 20 (0–
777) and 17 (0–459) PVCs/hour in Groups 1 and 2, respectively,
compared with 16 (0–1007) and 15 (0–764) during the OFF
periods. In addition, there were no significant differences in
other Holter parameters between baseline and follow-up in
either group.
Discussion
A large number of patients have symptomatic heart failure, despite
all available treatments. Although CRT is a viable option for such
patients also having dyssynchronous ventricular activation/contrac-
tion, ,50% of heart failure patients meet criteria for implantation
of a CRT device.2 In addition, as many as 30% of patients receiving
a CRT device are considered as ‘nonresponders’.12 Thus, a treat-
ment delivered by an implantable pulse generator through standard
pacing leads that can provide similar clinical benefits in patients
independent of the synchrony of ventricular contraction could sig-
nificantly enhance the therapeutic armamentarium for heart failure.
Initial clinical study of CCM involved short-term (10–30 min)
signal application using temporarily placed electrodes.5 The
results of those studies showed the feasibility of delivering CCM
treatment and demonstrated that left ventricular systolic perform-
ance could be acutely enhanced as was shown in earlier pre-clinical
studies.4 Other studies showed these acute enhancements of con-
tractile state were not associated with changes in myocardial
oxygen consumption.13,14 Most recently, a multicentre, double
blind feasibility study of 49 patients in the USA provided additional
confirmations of safety and, despite the small number of patients,
trends in efficacy with regard to exercise tolerance and quality
of life.8 Fashioned after the MUSTIC (Multisite Stimulation in Car-
diomyopathies) study of CRT,15 the present study represents the
next important step in the clinical evaluation of CCM as a
therapy for heart failure.
Patients who showed an acute response to CCM (93% of
enrolled patients) were randomly assigned to immediate CCM
treatment or sham treatment for 3 months, followed by crossover
to the opposite group for an additional 3 months. A significant
placebo effect (much more pronounced than reported in similar
studies) was observed in the present study so that efficacy par-
ameters improved significantly and similarly in both treatment
and control groups during the first phase of the study. This can
be attributed to the extreme measures taken to ensure blinding
of both patients and investigators during the study period.
During study Phase II, following crossover, patients switched to
active treatment demonstrated maintained or even continued clini-
cal improvement, whereas those crossing to sham treatment gen-
erally showed a return in clinical status back towards baseline such
that there were statistically and clinically significant differences
between the groups in the primary endpoints. Although our analy-
sis showed no evidence of carryover effect from the first to second
phase of the study, the study had relatively low power to detect
such an effect. However, if a carryover were in fact present, it
would be evident in the group switched from active to sham
therapy (i.e. in Group 1), and not in the group switched from
sham to active therapy. Therefore, if carryover did exist, it
would likely have reduced the estimated treatment benefit, not
inflate it. Thus, in this regard, we believe that the estimates of
the treatment effects are conservative.
With regard to safety, two patients died following implant, but
prior to randomization or CCM signal delivery; although there
was no specific link between these deaths and adverse events, it
cannot be excluded that factors related to the implant were con-
tributory. Overall, the incidences of death and adverse events were
relatively low and were balanced between active and sham treat-
ment during the randomized phases of the study. There was a
trend for a reduction in hospitalizations in patients receiving
active treatment. On the whole, this suggests that this form of
treatment is safe in the target patient population with a trend
for reduction in hospitalizations.
In order to put the present results into clinical perspective, it is
relevant to compare and contrast our findings with CCM in CHF
patients with narrow QRS duration to those obtained in CHF
patients with prolonged QRS duration in response to CRT. As
noted above, the present randomized, 3-month double blind, cross-
over study design was fashioned after the MUSTIC study of CRT.15
Thus, the results of that study are most pertinent. The MLWHFQ
results of the two studies are compared in Figure 5. Figure 5A
shows results from Group 1 patients (device ‘on’ first, then ‘off’)
whereas Figure 5B shows results from Group 2 (device ‘off’ first,
then ‘on’). As seen, results in Group 1 patients are nearly identical
in both studies for both ‘on’ and ‘off’ phases. In Group 2 patients,
the placebo effect is much more prominent in the present CCM
study, i.e. patients with device ‘off’ first showed little improvement
in the MUSTIC study. Thus, the main difference in findings
between the studies is explained by the lack of a placebo effect in
the MUSTIC study. These findings are similar to those obtained
with the 6MW test as shown in Figure 5C and D. With regard to
VO2,peak, comparison of results from several studies of CRT in
patients with prolonged QRS duration (all showing results with 6
months of treatment except for the MUSTIC study)12,15–17 to
those of the present study are shown in Figure 6. Also included are
the previously published results of a double blind placebo controlled
feasibility study of CCM in patients followed for 6 months (Phase 1 of
the FIX-HF-5 study).8 As seen, the overall impact of CCM on
VO2,peak is slightly less than that reported in the studies of CRT.
Thus, on the whole, the findings of the present study show CCM
to be of comparable impact on quality of life and exercise tolerance
as CRT, albeit in a different patient population.
Ongoing basic research focuses on newly recognized mechanisms
by which myocardial properties appear to be influenced by CCM
signals, particularly in the chronic setting. For example, results of
recent studies suggest that within 6 h of CCM signal delivery,
there are significant changes in myocardial gene expression (includ-
ing a reversal of several aspects of the foetal gene programme
expressed in heart failure), improved expression, and phosphoryl-
ation of the sodium–calcium exchanger, phospholamban, and con-
nexin 43.7 Restoration of normal gene expression profiles have
also been confirmed in a subset of the patients participating in the
present study as summarized in a recent preliminary report.18
One potential concern associated with the concept of CCM
treatment relates to its inotropic actions. Prior attempts at
pharmacological inotropic therapy with b-agonists and phosphodi-
esterase inhibitors (i.e. milrinone), which act directly via cAMP
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mechanisms, resulted in worsened outcomes.19 However, we have
seen more recently that the mechanism by which inotropy is
achieved impacts on the safety profile of a particular treatment.
For example, b-blockers and CRT, treatments which increase ven-
tricular contractile strength via mechanisms not directly related to
cAMP pathways, are associated with improved survival. In addition,
the use of b-blockers and ICDs have been introduced since the
early studies of inotropic agents; these treatments have the poten-
tial to impact on the safety profile of other forms of treatment.
Available evidence from animal models and patients indicate that
CCM enhances contractile performance without increasing myo-
cardial oxygen consumption. Furthermore, clinical studies available
thus far have shown lack of increases in ambient ectopy.20 The
present study adds significantly to the body of evidence suggesting
CCM treatment to be safe and devoid of deleterious effect on the
myocardium with regard to both contractile performance and
arrhythmias (specifically, no noted increased incidences of ICD
firings or arrhythmic deaths).
Potential limitations
One limitation of this study is the relatively short duration to which
subjects were exposed to CCM treatment (3 months). Many
therapies, including b-blockers and CRT, require relatively long
Figure 6 Comparison of the effect of CCM on VO2,peak to that
observed in prior studies of CRT in patients with prolonged QRS
duration. Studies for comparison include MUSTIC,15 MIRACLE,12
Contak-CD,16 and MIRALCE ICD.17 In addition, results of one
prior feasibility study of CCM, the FIX-HF-5 (Phase I), which
measured anaerobic threshold as the primary endpoint is also
included.8
Figure 5 Results of the present study are compared with those of the MUSTIC study15 of cardiac resynchronization therapy. A and C show
MLWHFQ and 6MW results from study subjects in which the respective device was ‘ON’ for the first 3 months and ‘OFF’ for the second three
months. B and D show results for same parameters from study subjects in which the respective device was ‘OFF’ for the first 3 months and ‘ON’
for the second three months. The main difference in the results of the two studies for both parameters is in Study Group 2, first study phase;
subjects in the present study show a placebo effect which is absent from the MUSTIC study. See text for further details.
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time periods to reach their maximal effects. Thus, it is possible, if
not likely, that the clinical impact of CCM treatment may continue
to grow over longer periods of time. One aspect where this is
most evident is the lack of detectible changes in the echocardiogra-
phically determined EF. This position is reinforced by experience
with CRT; results of the MIRACLE study showed that after 3
months of treatment, there was only a 1.5% difference increase
in EF in the treatment compared with the control group.21 With
6 months of follow-up, several studies of CRT show more signifi-
cant increases in EF over sham treatment (e.g. a 2.3% increase in
the CONTAK CD study16 and 4.8% increase in the MIRACLE
study12), as well as an 3 mm reduction in end-diastolic dimen-
sion.12,16 In contrast, however, no changes in EF or dimension
were found in the MIRACLE-ICD study even after 6 months.17
Under the assumption that CCM has a similar impact on function,
and given the relatively small number of patients who had
follow-up echocardiograms (45 per group) and inherent variabil-
ity in echocardiography, it would not be possible to detect a
change of this magnitude. Interestingly, changes in EF and LV size
were not reported in the MUSTIC study,15 perhaps also because
of the relatively short (3 month) duration of follow-up and rela-
tively small number of patients.
Another aspect of this study is the relatively large placebo effect
that was noted during study Phase I. Patients in this study received
a significant amount of medical attention by treating physicians,
nurses, and other study-related personnel. Patients in both
groups returned for clinical and device evaluations very frequently;
a total of six visits following implantation over a 6-month period,
two within the first month in addition to the implant procedure.
This could have contributed significantly to the placebo effect.
This high level of medical attention may have also contributed to
the relatively low observed rate of hospitalizations and mortality.
As in all studies, missing data are a potential limitation that needs
to be considered. The missing data in this study are relatively
balanced across study periods and between treatment groups.
We imputed missing data and found results nearly identical to
those obtained from the complete case analysis. The concordance
of results from different analyses speaks to the robustness of the
conclusions.
Patients with permanent atrial fibrillation were excluded from
the study because the OPTIMIZER device, in its current configur-
ation, requires detection of an appropriately timed P wave as part
of a safety algorithm that ensures CCM signals are never delivered
during the vulnerable period where they might insight an arrhyth-
mia. New algorithms have been developed to overcome this tech-
nical limitation which will ultimately permit use and testing of CCM
in patients with atrial fibrillation and also eliminate the need for the
atrial lead.
The current study has explored application of CCM signals for
7 h per day. Prior studies have employed 3, 5, and 7 h per
day.8,22 It is likely that further up-titration of the number of
hours per day could result in larger clinical effects.
Finally, patients enrolled in the study averaged 59 years of age
and were predominantly male. Although the average age is repre-
sentative of patients enrolling in current heart failure studies, it
should be noted that the general heart failure population includes
older individuals and a greater proportion of females.
Summary and conclusions
The results of the present study contribute to the growing body of
literature showing that exercise tolerance and quality of life are
better during CCM treatment and the treatment is safe when
applied over a 3-month period. These findings are a pivotal step
in the evaluation of this new and novel treatment modality pro-
vided by the OPTIMIZER System as a therapy for heart failure.
Larger scale studies of safety and effectiveness of CCM signals
are underway. If those studies are confirmatory of the current find-
ings, a new treatment will be made available to patients with other-
wise untreatable symptoms.
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